doTERRA Peppermint Enteric Coated Softgels 60

doTERRA Peppermint Enteric-Coated Softgels

These softgels put Peppermint essential oil into a convenient, pre-measured enteric-coated format designed to delay release compared with a standard softgel. They are a practical option for customers who want an internal Peppermint format without measuring oil from a bottle.

Why Customers Choose Them

• 60 enteric-coated softgels

• Contains Peppermint essential oil

• Pre-measured, portable supplement format

• Enteric coating is designed for delayed release

• Convenient alternative to bottled Peppermint oil for customers who prefer capsules

Ginny's Note

I’ve personally used these Peppermint Softgels. The enteric-coated format is one reason this product is especially interesting to compare with the research, because many human Peppermint-oil studies also used delayed-release or enteric-coated capsules. If you’re comparing these with Peppermint oil, Peppermint Touch, DigestZen, or another digestive-product format, call or text me at 619-851-8236.

What Research Is Exploring

Peppermint oil is one of the essential oils with a relatively substantial human evidence base for digestive symptoms, and much of that research used enteric-coated capsules—a closer formulation match to this product than inhalation or topical studies would be. A 2022 systematic review and meta-analysis included 10 randomized controlled trials with 1,030 people with irritable bowel syndrome (IBS). Pooled results favored peppermint oil for global IBS symptoms and abdominal pain, but adverse events were more frequent and the authors rated the quality of evidence as very low. Heartburn or reflux is a recurring adverse effect in this literature. Importantly, more rigorous individual trials have produced mixed results. A 2021 randomized double-blind placebo-controlled trial using enteric-coated peppermint oil found substantial improvement in both groups but no statistically significant difference between peppermint oil and placebo. A larger 2020 randomized trial of 190 participants likewise did not meet its primary endpoints for abdominal-pain response or overall IBS relief, although the small-intestinal-release formulation improved several secondary symptom measures. This is a useful example of why pooled evidence and individual high-quality trials should be considered together. The published studies also used specific doses and release technologies, so they should not be assumed to be identical to doTERRA's formulation or serving directions.

Read the 2022 peppermint-oil systematic review and meta-analysis on PubMed Read the 2021 enteric-coated peppermint-oil randomized trial on PubMed Read the 2020 peppermint-oil randomized trial on PubMed

Use: Follow the serving directions on the current product label. Swallow softgels as directed; do not substitute research-study dosing for the product-label directions.

Caution: Follow all current label precautions. Peppermint-oil capsule studies report gastrointestinal adverse effects including heartburn or reflux in some participants. If pregnant, nursing, taking medication, or under medical care, consult your healthcare professional before using dietary supplements.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.